SlideShare a Scribd company logo
ICH GUIDELINES
PRESENTED BY:
ABDUL NAIM
M-PHARM I YEAR
PHARMACEUTICS
DEPARTMENT
ICH
• ICH is the “International Conference on Harmonization of Technical Requirements for
Registration of Pharmaceuticals for Human Use”.
• ICH is a joint initiative involving both regulators and research-based industry representatives
of the EU, Japan and the US in scientific and technical discussions of the testing procedures
required to assess and ensure the safety, quality and efficacy of medicines.
OBJECTIVES OF ICH :
• To increase international harmonization of technical requirements.
• To ensure that safe, effective and high-quality medicines are developed.
• To harmonize technical requirements for registration or marketing approval.
• To develop and register pharmaceuticals in the most efficient and cost-effective manner.
• To promote public health.
• To prevent unnecessary duplication of clinical trials on humans.
• To minimize the use of animal testing without compromising safety and effectiveness of
drug.
MEMBERS OF ICH:
ICH is comprised of representatives from six parties that represent the regulatory bodies and research-based
industry in the European Union, Japan and the USA.
• Ministry of Health, Labor and Welfare (MHLW)
• Japan Pharmaceutical Manufacturers Association (JPMA)
In Japan
• European Union (EU),
• European Federation of Pharmaceutical Industries and Associations (EFPIA)
In Europe
• Food and Drug Administration (FDA)
• Pharmaceutical Research and Manufacturers of America (PhRMA)
In the USA
• Observers from the World Health Organization (WHO)
• European Free Trade Association (EFTA)
Additional members
*The Observers represent non-ICH countries and regions.
ICH
structure
ICH Assembly
ICH
Management
committee
MedDRA
Management
committee and
ICH
Secretariat
ICH ASSEMBLY: It works in bringing together all
Members and Observers of the ICH Association. It
takes decisions on particular matters such as on the
adoption of ICH Guidelines, admission of new
Members and Observers, and the ICH Associations
work plans and budget.
ICH MANAGEMENT COMMITTEE: It is that
body which supervises the operational aspects of
ICH on behalf of all Members, including
administrative and financial matters and oversight of
the Working Groups {WGs}.
MedDRA MANAGEMENT COMMITTEE: It is
responsible for managing, supporting, and
facilitating the maintenance, development of
MedDRA.
ICH SECRETARIAT: It is responsible for day-to-
day management of ICH, coordinating ICH activities
as well as providing support to the assembly, the MC
and Working Groups and MedDRA.
"Quality" Topics: i.e., those relating to chemical and pharmaceutical
Quality Assurance (Stability Testing, Impurity Testing, etc.)
" Efficacy" Topics: i.e., those relating to clinical studies in human
subject (Dose Response Studies, Good Clinical Practices, etc.)
" Safety" Topics: i.e., those relating to in vitro and in vivo pre-clinical
studies (Carcinogenicity Testing, Genotoxicity Testing, etc.)
" Multidisciplinary" Topics: i.e., cross-cutting Topics which do
not fit uniquely into one of the above categories.
QUALITY GUIDELINES
Q1A-Q1F---STABILITY:
Q1A : Stability Testing of New Drug Substances and Products
The purpose of stability testing is to provide evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of
environmental factors such as temperature, humidity, and light, and to establish a re-test
period for the drug substance or a shelf life for the drug product.
Q1B: Photostability Testing of New Drug Substances and Products Give guidance on
the basic testing protocol required to evaluate the light sensitivity and stability of new
drugs and products.
Q1C: Stability Testing for New Dosage Forms Gives guidelines for new formulations of
already approved medicines and defines the circumstances under which reduced stability
data can be accepted.
Q1D: Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and
products.
Q1E: Evaluation of Stability Data This guideline addresses the evaluation of stability data that
should be submitted in registration applications for new molecular entities and associated drug
products. The guideline provides recommendations on establishing shelf lives for drug substances
and drug products intended for storage at or below “room temperature”.
Q1F: Stability Data Package for Registration Applications in Climatic Zones III and IV. Describes
harmonized global stability testing requirements in order to facilitate access to medicines by
reducing the number of different storage conditions.
Q2-Analytical validation
Q2(R1): Validation of Analytical Procedures: Text and Methodology: The objective of validation of
an analytical procedure is to demonstrate that it is suitable for its intended purpose. Gives validation
parameters needed for a variety of analytical methods. It also discusses the characteristics that must
be considered during the validation of the analytical procedure.
Q3A- Q3D----Impurities
Q3A(R2): Impurities in New Drug Substances
The guideline addresses the chemistry and safety aspects of impurities, including the listing
of impurities, threshold limit, identification and quantification.
Classification of Impurities are of 3 types :
1. Organic impurities (process- and drug-related)
2. Inorganic impurities
3. Residual solvents
Q3B(R2): Impurities in New Drug Products
Q3C(R4): Impurities: Guideline for Residual Solvent
Benzene 2ppm Chlorobenzene 360ppm
Carbon tetrachloride 4ppm Formamide, Hexane 290ppm
Dichloromethane 5ppm Toluene 890ppm
Dichloroethane 8ppm Pyridine 200pm
Acetonitrile 410ppm Nitromethane 50ppm
Chloroform 60ppm Methanol 3000ppm
Q4: Pharmacopoeias
Q4A: Pharmacopeial Harmonization
Q4B: Evaluation and Recommendation of Pharmacopeial Texts for use in the ICH
regions.
This document describes a process for the evaluation and recommendation given by the
Q4B Expert Working Group (EWG) for selecting pharmacopeial texts to facilitate their
recognition by regulatory authorities for use, interchangeable in the ICH regions.
Q5A-Q5E---Quality of biotechnological products
Q5A(R1): Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines
of Human or Animal Origin
This document is concerned with testing and evaluation of the viral safety of biotechnology
products derived from cell lines of human or animal origin (i.e., mammalian, avian, insect).
The objective is to provide a general framework for virus testing experiments for the
evaluation of virus clearance and the design of viral tests and clearance evaluation studies.
Q5B: Quality of Biotechnological Products
Q5C: Stability Testing of Biotechnological/Biological Products.
Q5D: Derivation and Characterization of Cell Substrates Used for Production of
Biotechnological/Biological Products.
The objective of this guideline is to provide broad guidance on appropriate standards for cell
substrates.
Q5E: Comparability of Biotechnological/ Biological Products Subject to Changes in
Their Manufacturing Process
The objective of this document is to provide principles for assessing the comparability of
biotechnological/ biological products before and after changes are made in the manufacturing
process for the drug substance or drug product.
Therefore, this guideline is intended to assist in the collection of relevant technical
information which serves as evidence that the manufacturing process changes will not have
an adverse impact on the quality, safety and efficacy of the drug product.
Q6: Specifications for New Drug Substances and Products
Bulk drug substance and final product specifications are key parts of the core documentation
for world-wide product license applications.
This leads to conflicting standards for the same product, increased expenses and
opportunities for error as well as a potential cause for interruption of product supply.
Q6A: Specifications:
Test Procedures and Acceptance Criteria for New Drug Substances and New Drug
Products : Chemical Substances
The main objective of this guideline is to establish a single set of global specifications for
new drug substances and new drug products.
A specification is defined as a list of tests, references to analytical procedures, and
appropriate acceptance criteria, which are numerical limits, ranges.
This guideline addresses specifications, i.e., those tests, procedures, and acceptance criteria
which play a major role in assuring the quality of the new drug substance and new drug
product during shelf life.
Q6B: Specifications:
Test Procedures and Acceptance Criteria for Biotechnological/Biological Products
This document provides guidance on justifying and setting specifications for proteins and
polypeptides which are derived from recombinant or non-recombinant cell cultures. A valid
biological assay to measure the biological activity should be provided by the manufacturer.
Examples of procedures used to measure biological activity include:
• Animal-based biological assays, which measure an organism's biological response to the
product;
• Cell culture-based biological assays, which measure biochemical or physiological
response at the cellular level;
• Biochemical assays, which measure biological activities such as enzymatic reaction rates
or biological responses induced by immunological interactions.
Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
The main objective of this guideline is that to maintain the quality of the active
pharmaceutical ingredients.
Q8(R2): Pharmaceutical Development
This guideline is intended to provide guidance on the contents of Pharmaceutical
Development of drug products.
The aim of pharmaceutical development is to design a quality product and its manufacturing
process to consistently deliver the intended performance of the product. The Pharmaceutical
Development section also describe the type of dosage form and the formulation that are
suitable for the intended use.
Q8 gives information about Drug Substance, Excipients, Container Closure System.
Q9: Quality Risk Management
The purpose of this document is to offer a systematic approach to quality risk management.
This guideline provides principles and tools for quality risk management that can be applied
to all aspects of pharmaceutical quality including development, manufacturing, distribution;
and the inspection and submission/review processes throughout the lifecycle of drug
substances and drug (medicinal) products, biological and biotechnological products,
including the use of raw materials, solvents, excipients, packaging and labeling materials.
Q10: Pharmaceutical Quality System
This document establishes a new ICH guideline describing a model for an effective
quality management system for the pharmaceutical industry, referred to as the
Pharmaceutical Quality System.
Comprehensive model for an effective pharmaceutical quality system is based on
International Standards Organization (ISO) quality concepts, includes applicable Good
Manufacturing Practice (GMP) regulations.
THANK YOU

More Related Content

What's hot

Ind (investigational new drug application) and nda
Ind (investigational new drug application) and ndaInd (investigational new drug application) and nda
Ind (investigational new drug application) and nda
swati2084
 
Q1A(R2): STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS
Q1A(R2): STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTSQ1A(R2): STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS
Q1A(R2): STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS
Bhaumik Bavishi
 
Orange book
Orange bookOrange book
Orange book
Rucha Pathak
 
Hatch waxman act
Hatch waxman actHatch waxman act
STABILITY TESTING DURING PRODUCT DEVELOPMENT
STABILITY TESTING DURING PRODUCT DEVELOPMENTSTABILITY TESTING DURING PRODUCT DEVELOPMENT
STABILITY TESTING DURING PRODUCT DEVELOPMENT
Amruta Balekundri
 
Regulation of herbal drugs in india
Regulation of herbal drugs in indiaRegulation of herbal drugs in india
Regulation of herbal drugs in india
Richa Patel
 
Distribution records
Distribution recordsDistribution records
Distribution records
JyotiMhoprekar
 
Common Technical Document
Common Technical DocumentCommon Technical Document
Common Technical Document
Dr Sukanta sen
 
Regulatory affairs, Regulatory requirements for drug approval.pptx
Regulatory affairs, Regulatory  requirements for drug  approval.pptxRegulatory affairs, Regulatory  requirements for drug  approval.pptx
Regulatory affairs, Regulatory requirements for drug approval.pptx
PawanDhamala1
 
ICH [ Q ] Guidelines
ICH [ Q ] GuidelinesICH [ Q ] Guidelines
ICH [ Q ] Guidelines
AbhishekPatil387
 
eCTD
eCTDeCTD
The introduction of an orange book
The introduction of an orange bookThe introduction of an orange book
The introduction of an orange book
indus university-icri
 
CTD and eCTD Seminar.pptx
CTD and eCTD Seminar.pptxCTD and eCTD Seminar.pptx
CTD and eCTD Seminar.pptx
Preeti Kulkarni
 
ICH guidelines (Q,S,E,M)
ICH guidelines (Q,S,E,M)ICH guidelines (Q,S,E,M)
ICH guidelines (Q,S,E,M)
AshwiniBawankule
 
schedule M & Y
schedule M & Yschedule M & Y
schedule M & Y
joan vijetha
 
Investigational New Drug Application
Investigational New Drug ApplicationInvestigational New Drug Application
Investigational New Drug Application
Suhas Reddy C
 
Ctd ppt
Ctd pptCtd ppt
Common Technical Document (CTD)
Common Technical Document (CTD)Common Technical Document (CTD)
Common Technical Document (CTD)
Swapnil Fernandes
 
Unit-III, Chapter 1. Registration of Indian Products in Overseas Market.
Unit-III, Chapter 1. Registration of Indian Products in Overseas Market.Unit-III, Chapter 1. Registration of Indian Products in Overseas Market.
Unit-III, Chapter 1. Registration of Indian Products in Overseas Market.
Audumbar Mali
 
ICH safety guidelines
ICH safety guidelinesICH safety guidelines
ICH safety guidelines
vishnu Jatoth
 

What's hot (20)

Ind (investigational new drug application) and nda
Ind (investigational new drug application) and ndaInd (investigational new drug application) and nda
Ind (investigational new drug application) and nda
 
Q1A(R2): STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS
Q1A(R2): STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTSQ1A(R2): STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS
Q1A(R2): STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS
 
Orange book
Orange bookOrange book
Orange book
 
Hatch waxman act
Hatch waxman actHatch waxman act
Hatch waxman act
 
STABILITY TESTING DURING PRODUCT DEVELOPMENT
STABILITY TESTING DURING PRODUCT DEVELOPMENTSTABILITY TESTING DURING PRODUCT DEVELOPMENT
STABILITY TESTING DURING PRODUCT DEVELOPMENT
 
Regulation of herbal drugs in india
Regulation of herbal drugs in indiaRegulation of herbal drugs in india
Regulation of herbal drugs in india
 
Distribution records
Distribution recordsDistribution records
Distribution records
 
Common Technical Document
Common Technical DocumentCommon Technical Document
Common Technical Document
 
Regulatory affairs, Regulatory requirements for drug approval.pptx
Regulatory affairs, Regulatory  requirements for drug  approval.pptxRegulatory affairs, Regulatory  requirements for drug  approval.pptx
Regulatory affairs, Regulatory requirements for drug approval.pptx
 
ICH [ Q ] Guidelines
ICH [ Q ] GuidelinesICH [ Q ] Guidelines
ICH [ Q ] Guidelines
 
eCTD
eCTDeCTD
eCTD
 
The introduction of an orange book
The introduction of an orange bookThe introduction of an orange book
The introduction of an orange book
 
CTD and eCTD Seminar.pptx
CTD and eCTD Seminar.pptxCTD and eCTD Seminar.pptx
CTD and eCTD Seminar.pptx
 
ICH guidelines (Q,S,E,M)
ICH guidelines (Q,S,E,M)ICH guidelines (Q,S,E,M)
ICH guidelines (Q,S,E,M)
 
schedule M & Y
schedule M & Yschedule M & Y
schedule M & Y
 
Investigational New Drug Application
Investigational New Drug ApplicationInvestigational New Drug Application
Investigational New Drug Application
 
Ctd ppt
Ctd pptCtd ppt
Ctd ppt
 
Common Technical Document (CTD)
Common Technical Document (CTD)Common Technical Document (CTD)
Common Technical Document (CTD)
 
Unit-III, Chapter 1. Registration of Indian Products in Overseas Market.
Unit-III, Chapter 1. Registration of Indian Products in Overseas Market.Unit-III, Chapter 1. Registration of Indian Products in Overseas Market.
Unit-III, Chapter 1. Registration of Indian Products in Overseas Market.
 
ICH safety guidelines
ICH safety guidelinesICH safety guidelines
ICH safety guidelines
 

Similar to ICH GUIDELINES.pptx

ichguidelines_Final.ppt
ichguidelines_Final.pptichguidelines_Final.ppt
ichguidelines_Final.ppt
TridevSastri1
 
1.3 ICH .pdf
1.3 ICH .pdf1.3 ICH .pdf
1.3 ICH .pdf
KoriyaKrupali1
 
ICH guidelines
ICH  guidelinesICH  guidelines
ICH guidelines
monika maan
 
ICH.pptx
ICH.pptxICH.pptx
Ich quality guidelines
Ich quality guidelinesIch quality guidelines
Ich quality guidelines
SAMEERS17
 
ICH Guidelines pdf By Dr. Abhishek Pandey BP606.pdf
ICH Guidelines pdf By Dr. Abhishek  Pandey BP606.pdfICH Guidelines pdf By Dr. Abhishek  Pandey BP606.pdf
ICH Guidelines pdf By Dr. Abhishek Pandey BP606.pdf
SumanthM39
 
1.5 international conference on harmonization
1.5 international conference on harmonization1.5 international conference on harmonization
1.5 international conference on harmonization
Shital Patil
 
Ich guidelines
Ich guidelinesIch guidelines
Quality management systems qms tqm
Quality management systems qms tqmQuality management systems qms tqm
Quality management systems qms tqm
Dr Ajay Kumar Tiwari
 
ICH GUIDELINES.pptx
ICH GUIDELINES.pptxICH GUIDELINES.pptx
ICH GUIDELINES.pptx
BALASUNDARESAN M
 
EU(European Union) and ICH Guidelines
EU(European Union) and ICH GuidelinesEU(European Union) and ICH Guidelines
EU(European Union) and ICH Guidelines
D.R. Chandravanshi
 
ICH - quality guidelines
ICH - quality guidelinesICH - quality guidelines
ICH - quality guidelines
ManishShankarpure
 
ICH QSEM Guidelines
ICH QSEM GuidelinesICH QSEM Guidelines
ICH QSEM Guidelines
AshwinDigarse
 
ICH guidelines Q & S .pptx
ICH guidelines Q & S .pptxICH guidelines Q & S .pptx
ICH guidelines Q & S .pptx
nishenandansuryawans
 
Ich
IchIch
ICH ( International Conference on Harmonization) guidelines
ICH ( International Conference on Harmonization) guidelinesICH ( International Conference on Harmonization) guidelines
ICH ( International Conference on Harmonization) guidelines
ApekshaRajguru
 
Ich
IchIch
cmc [ chemistry manufacturing control ]
cmc [ chemistry manufacturing control ]cmc [ chemistry manufacturing control ]
cmc [ chemistry manufacturing control ]
Akshay Patil
 
Ichguidelines imp
Ichguidelines impIchguidelines imp
Ichguidelines imp
PRANJAY PATIL
 
Ich – quality guidelines
Ich – quality guidelinesIch – quality guidelines
Ich – quality guidelines
Harishankar Sahu
 

Similar to ICH GUIDELINES.pptx (20)

ichguidelines_Final.ppt
ichguidelines_Final.pptichguidelines_Final.ppt
ichguidelines_Final.ppt
 
1.3 ICH .pdf
1.3 ICH .pdf1.3 ICH .pdf
1.3 ICH .pdf
 
ICH guidelines
ICH  guidelinesICH  guidelines
ICH guidelines
 
ICH.pptx
ICH.pptxICH.pptx
ICH.pptx
 
Ich quality guidelines
Ich quality guidelinesIch quality guidelines
Ich quality guidelines
 
ICH Guidelines pdf By Dr. Abhishek Pandey BP606.pdf
ICH Guidelines pdf By Dr. Abhishek  Pandey BP606.pdfICH Guidelines pdf By Dr. Abhishek  Pandey BP606.pdf
ICH Guidelines pdf By Dr. Abhishek Pandey BP606.pdf
 
1.5 international conference on harmonization
1.5 international conference on harmonization1.5 international conference on harmonization
1.5 international conference on harmonization
 
Ich guidelines
Ich guidelinesIch guidelines
Ich guidelines
 
Quality management systems qms tqm
Quality management systems qms tqmQuality management systems qms tqm
Quality management systems qms tqm
 
ICH GUIDELINES.pptx
ICH GUIDELINES.pptxICH GUIDELINES.pptx
ICH GUIDELINES.pptx
 
EU(European Union) and ICH Guidelines
EU(European Union) and ICH GuidelinesEU(European Union) and ICH Guidelines
EU(European Union) and ICH Guidelines
 
ICH - quality guidelines
ICH - quality guidelinesICH - quality guidelines
ICH - quality guidelines
 
ICH QSEM Guidelines
ICH QSEM GuidelinesICH QSEM Guidelines
ICH QSEM Guidelines
 
ICH guidelines Q & S .pptx
ICH guidelines Q & S .pptxICH guidelines Q & S .pptx
ICH guidelines Q & S .pptx
 
Ich
IchIch
Ich
 
ICH ( International Conference on Harmonization) guidelines
ICH ( International Conference on Harmonization) guidelinesICH ( International Conference on Harmonization) guidelines
ICH ( International Conference on Harmonization) guidelines
 
Ich
IchIch
Ich
 
cmc [ chemistry manufacturing control ]
cmc [ chemistry manufacturing control ]cmc [ chemistry manufacturing control ]
cmc [ chemistry manufacturing control ]
 
Ichguidelines imp
Ichguidelines impIchguidelines imp
Ichguidelines imp
 
Ich – quality guidelines
Ich – quality guidelinesIch – quality guidelines
Ich – quality guidelines
 

More from AbdulNaim14

informed consent process and procedure .pptx
informed consent process and procedure .pptxinformed consent process and procedure .pptx
informed consent process and procedure .pptx
AbdulNaim14
 
HECKEL PLOT CEUTICS .pptx
HECKEL PLOT CEUTICS .pptxHECKEL PLOT CEUTICS .pptx
HECKEL PLOT CEUTICS .pptx
AbdulNaim14
 
global submission of NDA .pptx
global submission of NDA .pptxglobal submission of NDA .pptx
global submission of NDA .pptx
AbdulNaim14
 
global submission of ANDA .pptx
global submission of ANDA .pptxglobal submission of ANDA .pptx
global submission of ANDA .pptx
AbdulNaim14
 
post approval regulatory affairs
post approval regulatory affairspost approval regulatory affairs
post approval regulatory affairs
AbdulNaim14
 
types of validation
types of validation types of validation
types of validation
AbdulNaim14
 

More from AbdulNaim14 (6)

informed consent process and procedure .pptx
informed consent process and procedure .pptxinformed consent process and procedure .pptx
informed consent process and procedure .pptx
 
HECKEL PLOT CEUTICS .pptx
HECKEL PLOT CEUTICS .pptxHECKEL PLOT CEUTICS .pptx
HECKEL PLOT CEUTICS .pptx
 
global submission of NDA .pptx
global submission of NDA .pptxglobal submission of NDA .pptx
global submission of NDA .pptx
 
global submission of ANDA .pptx
global submission of ANDA .pptxglobal submission of ANDA .pptx
global submission of ANDA .pptx
 
post approval regulatory affairs
post approval regulatory affairspost approval regulatory affairs
post approval regulatory affairs
 
types of validation
types of validation types of validation
types of validation
 

Recently uploaded

DepEd School Calendar 2024-2025 DO_s2024_008
DepEd School Calendar 2024-2025 DO_s2024_008DepEd School Calendar 2024-2025 DO_s2024_008
DepEd School Calendar 2024-2025 DO_s2024_008
Glenn Rivera
 
JavaScript Interview Questions PDF By ScholarHat
JavaScript Interview  Questions PDF By ScholarHatJavaScript Interview  Questions PDF By ScholarHat
JavaScript Interview Questions PDF By ScholarHat
Scholarhat
 
slidesgo-mastering-the-art-of-listening-insights-from-robin-sharma-2024070718...
slidesgo-mastering-the-art-of-listening-insights-from-robin-sharma-2024070718...slidesgo-mastering-the-art-of-listening-insights-from-robin-sharma-2024070718...
slidesgo-mastering-the-art-of-listening-insights-from-robin-sharma-2024070718...
MANIVALANSR
 
MathematicsGrade7-Presentation-July-12024.pptx
MathematicsGrade7-Presentation-July-12024.pptxMathematicsGrade7-Presentation-July-12024.pptx
MathematicsGrade7-Presentation-July-12024.pptx
nolicaliso1
 
6. Physiological Disorder of fruits and vegetables.pptx
6. Physiological Disorder of fruits and vegetables.pptx6. Physiological Disorder of fruits and vegetables.pptx
6. Physiological Disorder of fruits and vegetables.pptx
UmeshTimilsina1
 
2024 Winter SWAYAM NPTEL & A Student.pptx
2024 Winter SWAYAM NPTEL & A Student.pptx2024 Winter SWAYAM NPTEL & A Student.pptx
2024 Winter SWAYAM NPTEL & A Student.pptx
Utsav Yagnik
 
FINAL MATATAG Science CG 2023 Grades 3-10.pdf
FINAL MATATAG Science CG 2023 Grades 3-10.pdfFINAL MATATAG Science CG 2023 Grades 3-10.pdf
FINAL MATATAG Science CG 2023 Grades 3-10.pdf
maritescanete2
 
5. Postharvest deterioration of fruits and vegetables.pptx
5. Postharvest deterioration of fruits and vegetables.pptx5. Postharvest deterioration of fruits and vegetables.pptx
5. Postharvest deterioration of fruits and vegetables.pptx
UmeshTimilsina1
 
Odoo 17 Events - Attendees List Scanning
Odoo 17 Events - Attendees List ScanningOdoo 17 Events - Attendees List Scanning
Odoo 17 Events - Attendees List Scanning
Celine George
 
Parkinson Disease & Anti-Parkinsonian Drugs.pptx
Parkinson Disease & Anti-Parkinsonian Drugs.pptxParkinson Disease & Anti-Parkinsonian Drugs.pptx
Parkinson Disease & Anti-Parkinsonian Drugs.pptx
AnujVishwakarma34
 
Dr. Nasir Mustafa CERTIFICATE OF APPRECIATION "NEUROANATOMY"
Dr. Nasir Mustafa CERTIFICATE OF APPRECIATION "NEUROANATOMY"Dr. Nasir Mustafa CERTIFICATE OF APPRECIATION "NEUROANATOMY"
Dr. Nasir Mustafa CERTIFICATE OF APPRECIATION "NEUROANATOMY"
Dr. Nasir Mustafa
 
11EHS Term 3 Week 1 Unit 1 Review: Feedback and improvementpptx
11EHS Term 3 Week 1 Unit 1 Review: Feedback and improvementpptx11EHS Term 3 Week 1 Unit 1 Review: Feedback and improvementpptx
11EHS Term 3 Week 1 Unit 1 Review: Feedback and improvementpptx
mansk2
 
E-learning Odoo 17 New features - Odoo 17 Slides
E-learning Odoo 17  New features - Odoo 17 SlidesE-learning Odoo 17  New features - Odoo 17 Slides
E-learning Odoo 17 New features - Odoo 17 Slides
Celine George
 
Lecture Notes Unit4 Chapter13 users , roles and privileges
Lecture Notes Unit4 Chapter13 users , roles and privilegesLecture Notes Unit4 Chapter13 users , roles and privileges
Lecture Notes Unit4 Chapter13 users , roles and privileges
Murugan146644
 
A beginner’s guide to project reviews - everything you wanted to know but wer...
A beginner’s guide to project reviews - everything you wanted to know but wer...A beginner’s guide to project reviews - everything you wanted to know but wer...
A beginner’s guide to project reviews - everything you wanted to know but wer...
Association for Project Management
 
SD_Integrating 21st Century Skills in Classroom-based Assessment.pptx
SD_Integrating 21st Century Skills in Classroom-based Assessment.pptxSD_Integrating 21st Century Skills in Classroom-based Assessment.pptx
SD_Integrating 21st Century Skills in Classroom-based Assessment.pptx
elwoodprias1
 
MATATAG CURRICULUM sample lesson exemplar.docx
MATATAG CURRICULUM sample lesson exemplar.docxMATATAG CURRICULUM sample lesson exemplar.docx
MATATAG CURRICULUM sample lesson exemplar.docx
yardenmendoza
 
MVC Interview Questions PDF By ScholarHat
MVC Interview Questions PDF By ScholarHatMVC Interview Questions PDF By ScholarHat
MVC Interview Questions PDF By ScholarHat
Scholarhat
 
ASP.NET Core Interview Questions PDF By ScholarHat.pdf
ASP.NET Core Interview Questions PDF By ScholarHat.pdfASP.NET Core Interview Questions PDF By ScholarHat.pdf
ASP.NET Core Interview Questions PDF By ScholarHat.pdf
Scholarhat
 
INSIDE OUT - PowerPoint Presentation.pptx
INSIDE OUT - PowerPoint Presentation.pptxINSIDE OUT - PowerPoint Presentation.pptx
INSIDE OUT - PowerPoint Presentation.pptx
RODELAZARES3
 

Recently uploaded (20)

DepEd School Calendar 2024-2025 DO_s2024_008
DepEd School Calendar 2024-2025 DO_s2024_008DepEd School Calendar 2024-2025 DO_s2024_008
DepEd School Calendar 2024-2025 DO_s2024_008
 
JavaScript Interview Questions PDF By ScholarHat
JavaScript Interview  Questions PDF By ScholarHatJavaScript Interview  Questions PDF By ScholarHat
JavaScript Interview Questions PDF By ScholarHat
 
slidesgo-mastering-the-art-of-listening-insights-from-robin-sharma-2024070718...
slidesgo-mastering-the-art-of-listening-insights-from-robin-sharma-2024070718...slidesgo-mastering-the-art-of-listening-insights-from-robin-sharma-2024070718...
slidesgo-mastering-the-art-of-listening-insights-from-robin-sharma-2024070718...
 
MathematicsGrade7-Presentation-July-12024.pptx
MathematicsGrade7-Presentation-July-12024.pptxMathematicsGrade7-Presentation-July-12024.pptx
MathematicsGrade7-Presentation-July-12024.pptx
 
6. Physiological Disorder of fruits and vegetables.pptx
6. Physiological Disorder of fruits and vegetables.pptx6. Physiological Disorder of fruits and vegetables.pptx
6. Physiological Disorder of fruits and vegetables.pptx
 
2024 Winter SWAYAM NPTEL & A Student.pptx
2024 Winter SWAYAM NPTEL & A Student.pptx2024 Winter SWAYAM NPTEL & A Student.pptx
2024 Winter SWAYAM NPTEL & A Student.pptx
 
FINAL MATATAG Science CG 2023 Grades 3-10.pdf
FINAL MATATAG Science CG 2023 Grades 3-10.pdfFINAL MATATAG Science CG 2023 Grades 3-10.pdf
FINAL MATATAG Science CG 2023 Grades 3-10.pdf
 
5. Postharvest deterioration of fruits and vegetables.pptx
5. Postharvest deterioration of fruits and vegetables.pptx5. Postharvest deterioration of fruits and vegetables.pptx
5. Postharvest deterioration of fruits and vegetables.pptx
 
Odoo 17 Events - Attendees List Scanning
Odoo 17 Events - Attendees List ScanningOdoo 17 Events - Attendees List Scanning
Odoo 17 Events - Attendees List Scanning
 
Parkinson Disease & Anti-Parkinsonian Drugs.pptx
Parkinson Disease & Anti-Parkinsonian Drugs.pptxParkinson Disease & Anti-Parkinsonian Drugs.pptx
Parkinson Disease & Anti-Parkinsonian Drugs.pptx
 
Dr. Nasir Mustafa CERTIFICATE OF APPRECIATION "NEUROANATOMY"
Dr. Nasir Mustafa CERTIFICATE OF APPRECIATION "NEUROANATOMY"Dr. Nasir Mustafa CERTIFICATE OF APPRECIATION "NEUROANATOMY"
Dr. Nasir Mustafa CERTIFICATE OF APPRECIATION "NEUROANATOMY"
 
11EHS Term 3 Week 1 Unit 1 Review: Feedback and improvementpptx
11EHS Term 3 Week 1 Unit 1 Review: Feedback and improvementpptx11EHS Term 3 Week 1 Unit 1 Review: Feedback and improvementpptx
11EHS Term 3 Week 1 Unit 1 Review: Feedback and improvementpptx
 
E-learning Odoo 17 New features - Odoo 17 Slides
E-learning Odoo 17  New features - Odoo 17 SlidesE-learning Odoo 17  New features - Odoo 17 Slides
E-learning Odoo 17 New features - Odoo 17 Slides
 
Lecture Notes Unit4 Chapter13 users , roles and privileges
Lecture Notes Unit4 Chapter13 users , roles and privilegesLecture Notes Unit4 Chapter13 users , roles and privileges
Lecture Notes Unit4 Chapter13 users , roles and privileges
 
A beginner’s guide to project reviews - everything you wanted to know but wer...
A beginner’s guide to project reviews - everything you wanted to know but wer...A beginner’s guide to project reviews - everything you wanted to know but wer...
A beginner’s guide to project reviews - everything you wanted to know but wer...
 
SD_Integrating 21st Century Skills in Classroom-based Assessment.pptx
SD_Integrating 21st Century Skills in Classroom-based Assessment.pptxSD_Integrating 21st Century Skills in Classroom-based Assessment.pptx
SD_Integrating 21st Century Skills in Classroom-based Assessment.pptx
 
MATATAG CURRICULUM sample lesson exemplar.docx
MATATAG CURRICULUM sample lesson exemplar.docxMATATAG CURRICULUM sample lesson exemplar.docx
MATATAG CURRICULUM sample lesson exemplar.docx
 
MVC Interview Questions PDF By ScholarHat
MVC Interview Questions PDF By ScholarHatMVC Interview Questions PDF By ScholarHat
MVC Interview Questions PDF By ScholarHat
 
ASP.NET Core Interview Questions PDF By ScholarHat.pdf
ASP.NET Core Interview Questions PDF By ScholarHat.pdfASP.NET Core Interview Questions PDF By ScholarHat.pdf
ASP.NET Core Interview Questions PDF By ScholarHat.pdf
 
INSIDE OUT - PowerPoint Presentation.pptx
INSIDE OUT - PowerPoint Presentation.pptxINSIDE OUT - PowerPoint Presentation.pptx
INSIDE OUT - PowerPoint Presentation.pptx
 

ICH GUIDELINES.pptx

  • 1. ICH GUIDELINES PRESENTED BY: ABDUL NAIM M-PHARM I YEAR PHARMACEUTICS DEPARTMENT
  • 2. ICH • ICH is the “International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use”. • ICH is a joint initiative involving both regulators and research-based industry representatives of the EU, Japan and the US in scientific and technical discussions of the testing procedures required to assess and ensure the safety, quality and efficacy of medicines. OBJECTIVES OF ICH : • To increase international harmonization of technical requirements. • To ensure that safe, effective and high-quality medicines are developed. • To harmonize technical requirements for registration or marketing approval. • To develop and register pharmaceuticals in the most efficient and cost-effective manner. • To promote public health. • To prevent unnecessary duplication of clinical trials on humans. • To minimize the use of animal testing without compromising safety and effectiveness of drug.
  • 3. MEMBERS OF ICH: ICH is comprised of representatives from six parties that represent the regulatory bodies and research-based industry in the European Union, Japan and the USA. • Ministry of Health, Labor and Welfare (MHLW) • Japan Pharmaceutical Manufacturers Association (JPMA) In Japan • European Union (EU), • European Federation of Pharmaceutical Industries and Associations (EFPIA) In Europe • Food and Drug Administration (FDA) • Pharmaceutical Research and Manufacturers of America (PhRMA) In the USA • Observers from the World Health Organization (WHO) • European Free Trade Association (EFTA) Additional members *The Observers represent non-ICH countries and regions.
  • 4. ICH structure ICH Assembly ICH Management committee MedDRA Management committee and ICH Secretariat ICH ASSEMBLY: It works in bringing together all Members and Observers of the ICH Association. It takes decisions on particular matters such as on the adoption of ICH Guidelines, admission of new Members and Observers, and the ICH Associations work plans and budget. ICH MANAGEMENT COMMITTEE: It is that body which supervises the operational aspects of ICH on behalf of all Members, including administrative and financial matters and oversight of the Working Groups {WGs}. MedDRA MANAGEMENT COMMITTEE: It is responsible for managing, supporting, and facilitating the maintenance, development of MedDRA. ICH SECRETARIAT: It is responsible for day-to- day management of ICH, coordinating ICH activities as well as providing support to the assembly, the MC and Working Groups and MedDRA.
  • 5. "Quality" Topics: i.e., those relating to chemical and pharmaceutical Quality Assurance (Stability Testing, Impurity Testing, etc.) " Efficacy" Topics: i.e., those relating to clinical studies in human subject (Dose Response Studies, Good Clinical Practices, etc.) " Safety" Topics: i.e., those relating to in vitro and in vivo pre-clinical studies (Carcinogenicity Testing, Genotoxicity Testing, etc.) " Multidisciplinary" Topics: i.e., cross-cutting Topics which do not fit uniquely into one of the above categories.
  • 6. QUALITY GUIDELINES Q1A-Q1F---STABILITY: Q1A : Stability Testing of New Drug Substances and Products The purpose of stability testing is to provide evidence on how the quality of a drug substance or drug product varies with time under the influence of a variety of environmental factors such as temperature, humidity, and light, and to establish a re-test period for the drug substance or a shelf life for the drug product. Q1B: Photostability Testing of New Drug Substances and Products Give guidance on the basic testing protocol required to evaluate the light sensitivity and stability of new drugs and products. Q1C: Stability Testing for New Dosage Forms Gives guidelines for new formulations of already approved medicines and defines the circumstances under which reduced stability data can be accepted.
  • 7. Q1D: Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and products. Q1E: Evaluation of Stability Data This guideline addresses the evaluation of stability data that should be submitted in registration applications for new molecular entities and associated drug products. The guideline provides recommendations on establishing shelf lives for drug substances and drug products intended for storage at or below “room temperature”. Q1F: Stability Data Package for Registration Applications in Climatic Zones III and IV. Describes harmonized global stability testing requirements in order to facilitate access to medicines by reducing the number of different storage conditions. Q2-Analytical validation Q2(R1): Validation of Analytical Procedures: Text and Methodology: The objective of validation of an analytical procedure is to demonstrate that it is suitable for its intended purpose. Gives validation parameters needed for a variety of analytical methods. It also discusses the characteristics that must be considered during the validation of the analytical procedure.
  • 8. Q3A- Q3D----Impurities Q3A(R2): Impurities in New Drug Substances The guideline addresses the chemistry and safety aspects of impurities, including the listing of impurities, threshold limit, identification and quantification. Classification of Impurities are of 3 types : 1. Organic impurities (process- and drug-related) 2. Inorganic impurities 3. Residual solvents Q3B(R2): Impurities in New Drug Products Q3C(R4): Impurities: Guideline for Residual Solvent Benzene 2ppm Chlorobenzene 360ppm Carbon tetrachloride 4ppm Formamide, Hexane 290ppm Dichloromethane 5ppm Toluene 890ppm Dichloroethane 8ppm Pyridine 200pm Acetonitrile 410ppm Nitromethane 50ppm Chloroform 60ppm Methanol 3000ppm
  • 9. Q4: Pharmacopoeias Q4A: Pharmacopeial Harmonization Q4B: Evaluation and Recommendation of Pharmacopeial Texts for use in the ICH regions. This document describes a process for the evaluation and recommendation given by the Q4B Expert Working Group (EWG) for selecting pharmacopeial texts to facilitate their recognition by regulatory authorities for use, interchangeable in the ICH regions. Q5A-Q5E---Quality of biotechnological products Q5A(R1): Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin This document is concerned with testing and evaluation of the viral safety of biotechnology products derived from cell lines of human or animal origin (i.e., mammalian, avian, insect). The objective is to provide a general framework for virus testing experiments for the evaluation of virus clearance and the design of viral tests and clearance evaluation studies.
  • 10. Q5B: Quality of Biotechnological Products Q5C: Stability Testing of Biotechnological/Biological Products. Q5D: Derivation and Characterization of Cell Substrates Used for Production of Biotechnological/Biological Products. The objective of this guideline is to provide broad guidance on appropriate standards for cell substrates. Q5E: Comparability of Biotechnological/ Biological Products Subject to Changes in Their Manufacturing Process The objective of this document is to provide principles for assessing the comparability of biotechnological/ biological products before and after changes are made in the manufacturing process for the drug substance or drug product. Therefore, this guideline is intended to assist in the collection of relevant technical information which serves as evidence that the manufacturing process changes will not have an adverse impact on the quality, safety and efficacy of the drug product.
  • 11. Q6: Specifications for New Drug Substances and Products Bulk drug substance and final product specifications are key parts of the core documentation for world-wide product license applications. This leads to conflicting standards for the same product, increased expenses and opportunities for error as well as a potential cause for interruption of product supply. Q6A: Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products : Chemical Substances The main objective of this guideline is to establish a single set of global specifications for new drug substances and new drug products. A specification is defined as a list of tests, references to analytical procedures, and appropriate acceptance criteria, which are numerical limits, ranges. This guideline addresses specifications, i.e., those tests, procedures, and acceptance criteria which play a major role in assuring the quality of the new drug substance and new drug product during shelf life.
  • 12. Q6B: Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products This document provides guidance on justifying and setting specifications for proteins and polypeptides which are derived from recombinant or non-recombinant cell cultures. A valid biological assay to measure the biological activity should be provided by the manufacturer. Examples of procedures used to measure biological activity include: • Animal-based biological assays, which measure an organism's biological response to the product; • Cell culture-based biological assays, which measure biochemical or physiological response at the cellular level; • Biochemical assays, which measure biological activities such as enzymatic reaction rates or biological responses induced by immunological interactions. Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients The main objective of this guideline is that to maintain the quality of the active pharmaceutical ingredients.
  • 13. Q8(R2): Pharmaceutical Development This guideline is intended to provide guidance on the contents of Pharmaceutical Development of drug products. The aim of pharmaceutical development is to design a quality product and its manufacturing process to consistently deliver the intended performance of the product. The Pharmaceutical Development section also describe the type of dosage form and the formulation that are suitable for the intended use. Q8 gives information about Drug Substance, Excipients, Container Closure System. Q9: Quality Risk Management The purpose of this document is to offer a systematic approach to quality risk management. This guideline provides principles and tools for quality risk management that can be applied to all aspects of pharmaceutical quality including development, manufacturing, distribution; and the inspection and submission/review processes throughout the lifecycle of drug substances and drug (medicinal) products, biological and biotechnological products, including the use of raw materials, solvents, excipients, packaging and labeling materials.
  • 14. Q10: Pharmaceutical Quality System This document establishes a new ICH guideline describing a model for an effective quality management system for the pharmaceutical industry, referred to as the Pharmaceutical Quality System. Comprehensive model for an effective pharmaceutical quality system is based on International Standards Organization (ISO) quality concepts, includes applicable Good Manufacturing Practice (GMP) regulations.